The document provides an overview of the Standards of Care in Diabetes - 2023 guidelines. It includes 17 sections that cover various aspects of diabetes care, treatment goals, and quality evaluation tools. The sections include classification and diagnosis of diabetes, prevention or delay of type 2 diabetes, medical evaluation and assessment of comorbidities, facilitating positive health behaviors, glycemic targets, pharmacologic treatment approaches, management of cardiovascular disease and other complications, and more. The guidelines are intended to provide clinicians, patients, and other stakeholders with an evidence-based framework for diabetes care and management.
Summary of american diabetes association 2014 guidelinesDr. Afzal Haq Asif
The document summarizes guidelines from the American Diabetes Association (ADA) 2014 standards of medical care for diabetes. It provides recommendations on diagnosing and testing for diabetes, treatment targets for blood glucose, blood pressure, and lipids. It also discusses pharmacologic therapy, monitoring, cardiovascular disease screening and treatment, and management of other diabetes-related health issues. The full source document from the ADA contains more detailed recommendations and evidence ratings.
This document provides guidelines from the American Diabetes Association for classifying, diagnosing, and screening for diabetes. It discusses recommendations for diagnosing type 1 diabetes, type 2 diabetes, gestational diabetes, and other specific types. It provides evidence-based guidance on using A1C testing, oral glucose tolerance tests, and other methods for diagnosis and screening in various populations and clinical settings. The document is intended to help clinicians properly classify, diagnose, and screen for diabetes and prediabetes.
This document provides guidelines from the American Diabetes Association for classifying, diagnosing, and screening for diabetes. It defines the main types of diabetes and recommends using A1C, fasting plasma glucose, or oral glucose tolerance tests to diagnose diabetes and prediabetes. It provides testing guidelines for gestational diabetes, cystic fibrosis-related diabetes, monogenic forms of diabetes, and screening recommendations for different populations. The guidelines are based on reviews of the latest scientific evidence and aim to improve diabetes classification and diagnosis.
The document provides a quick reference guide that summarizes recommendations from NICE on the management of rheumatoid arthritis in adults. It was developed by the National Collaborating Centre for Chronic Conditions and reviewed by healthcare professionals and patients. The guide outlines priorities for referral, use of disease-modifying drugs and biologicals, monitoring disease activity, and the roles of the multidisciplinary team and surgery in management. It is intended to help rheumatologists, GPs, and other staff caring for people with rheumatoid arthritis.
This slide deck summarizes the key recommendations from the American Diabetes Association's Standards of Medical Care in Diabetes - 2021. It contains content created and approved by the ADA that can be used freely in presentations with attribution. The slides provide guidelines on classifying and diagnosing diabetes, preventing or delaying type 2 diabetes, and improving care and promoting health in populations with a focus on team-based and patient-centered care. Updates to the living Standards document are made when new treatments or findings necessitate changes.
C1 cda canadian diabetes association guidelines 2013Diabetes for all
This document provides an introduction to the 2013 Canadian Diabetes Association Clinical Practice Guidelines. It summarizes key points, including:
- The guidelines were developed by a 120 member expert committee and are intended to guide best practices for diabetes prevention and management in Canada.
- Diabetes prevalence is increasing significantly worldwide and in Canada, posing a major health challenge.
- Delaying the onset of type 2 diabetes can provide significant health benefits through reduced cardiovascular disease and renal failure.
- Optimal diabetes care involves a team-based approach centered around self-management and addressing multiple risk factors and health behaviors to prevent complications.
This document discusses guidelines for managing chronic complications of diabetes, including microvascular and macrovascular complications. It provides an overview of the pathogenesis and risk factors for complications and reviews current guidelines from the American Diabetes Association (ADA) for screening, treating, and setting goals for hypertension, dyslipidemia, and cardiovascular disease in patients with diabetes. The guidelines recommend treating hypertension to a goal of <140/90 mmHg, prescribing statin therapy for diabetic patients above a certain age or risk level, and using antiplatelet agents for secondary prevention of cardiovascular events.
The document discusses treatment options for type 2 diabetes beyond metformin, focusing on balancing glycemic control, weight gain, and risk of hypoglycemia. It reviews factors to consider when selecting antihyperglycemic agents and assessing individual patient needs. A case study of a patient named Jason is presented at various stages over 5 years to demonstrate applying treatment principles in clinical practice.
1) The document summarizes guidelines from the American Diabetes Association's Standards of Medical Care in Diabetes for 2016. It covers recommendations for screening, diagnosing, treating, and managing diabetes and related conditions.
2) Key recommendations include targeting an A1C below 7% for most adults with diabetes, treating hypertension to a blood pressure of less than 140/90 mmHg, and providing diabetes self-management education and medical nutrition therapy to all patients.
3) The guidelines also recommend lifestyle management including physical activity and smoking cessation, as well as addressing psychosocial issues. Medications are recommended based on glycemic control levels and individual patient factors.
ADA 2022 STANDARDS OF CARE FOR PRIMARY CARE PROVIDERS.pdfssuser6e0ff8
This document provides an abridged summary of the 2022 Standards of Medical Care in Diabetes guidelines from the American Diabetes Association (ADA) for primary care providers. It summarizes the ADA's evidence-based recommendations for diagnosing and treating all forms of diabetes. The guidelines are developed by an expert multidisciplinary committee and updated annually based on the latest evidence. This abridged version focuses on the recommendations most pertinent to primary care providers, retaining the same numbering as the full guidelines.
This document provides an abridged summary of the 2022 Standards of Medical Care in Diabetes guidelines from the American Diabetes Association (ADA) for primary care providers. It summarizes the ADA's evidence-based recommendations for diagnosing and treating all forms of diabetes. The guidelines are developed by an expert multidisciplinary committee and updated annually based on the latest evidence. This abridged version focuses on the recommendations most pertinent to primary care providers and retains the same numbering as the full guidelines.
This document provides guidelines for managing type 2 diabetes in older adults aged 70 and over. It was created by an international group of diabetes experts to address the special issues related to providing high-quality diabetes care for older populations. The guidelines aim to individualize care based on a person's functional status and medical comorbidities. It provides recommendations in areas like cardiovascular risk, education, renal impairment, and end-of-life care. The guidelines also emphasize the importance of comprehensive geriatric assessments and involving informal caregivers in diabetes management for older adults.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries. For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources. The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
This document provides guidance for the management of type 2 diabetes that was developed by the National Collaborating Centre for Chronic Conditions. It is an update of previous NICE guidelines on various aspects of type 2 diabetes management. The guidance includes recommendations on patient education, lifestyle management, glucose control levels, medication therapies, management of complications, and implementation. It aims to provide best practice advice on the holistic care of people with type 2 diabetes.
The document discusses guidelines for diagnosing and classifying diabetes from the Standards of Medical Care in Diabetes - 2018. It covers:
1. Classifying diabetes into type 1, type 2, gestational diabetes, and other specific types.
2. Diagnostic tests for diabetes including hemoglobin A1c (A1c), fasting plasma glucose, and oral glucose tolerance tests.
3. Categories of increased risk for diabetes (prediabetes) defined as A1c of 5.7-6.4%, fasting plasma glucose of 100-125 mg/dL, or 2-hour plasma glucose of 140-199 mg/dL during an oral glucose tolerance test.
This document summarizes 10 key points for the management of overweight and obesity in adults. It addresses evaluating patients' BMI and waist circumference, counseling on weight loss benefits, recommending calorie-restricted diets and lifestyle programs for weight loss and maintenance, and the role of bariatric surgery. The points cover best practices for identifying patients who need weight loss, targeting modest 3-5% weight loss for health improvements, prescribing 6 month lifestyle programs including reduced calorie diets and exercise, and maintaining weight loss through long-term programs. Bariatric surgery is recommended for adults with a BMI ≥40 or ≥35 with comorbidities who have not achieved weight loss through other means.
Similar to Summary of Revisions: Standards of Care in Diabetes—2024 (20)
Module 7- Care Planning, Restorative Care, Documentation, Working in the Comm...Reliable Assignments Help
Module 7: Care Planning, Restorative Care, Documentation, Working in the Community Assignment Help
Are you feeling overwhelmed by your Module 7: Care Planning, Restorative Care, Documentation, and Working in the Community assignments? Look no further! At GPAShark.com, we offer expert assistance to help you excel in your coursework and achieve your academic goals.
Our Services Include:
Detailed Assignment Help: From defining ethical client-centered care to understanding the principles of professionalism and communication, we provide detailed assistance for all aspects of your assignments.
Report and Documentation Guidance: Learn how to effectively document and report client care, adhering to privacy legislation and confidentiality principles.
Rehabilitation and Restorative Care Planning: Get expert help in developing rehabilitation plans for various health conditions, understanding different rehabilitation settings, and working with rehabilitation teams.
Community Care Strategies: Master the nuances of working in the community, providing home care services, and contributing to client care planning through effective communication.
How to Get Started
Getting started with GPAShark.com is easy. Simply visit our website and fill out a request form with your assignment details. Our team will promptly get in touch with you to discuss your needs and how we can assist you. Let us take the stress out of your Module 7 assignments so you can focus on what matters most – your education and career growth.
Don’t let the complexities of care planning, restorative care, and community work overwhelm you. Reach out to GPAShark.com today and experience the difference expert assignment help can make!
Motivational Interviewing (MI) is a therapeutic approach that helps individuals find the motivation to make positive behavioral changes. By fostering a collaborative, empathetic, and non-judgmental dialogue, MI empowers clients to explore their ambivalence about change and strengthen their commitment to personal goals. This method is effective in various settings, including addiction treatment, health behavior change, and mental health.
A price that is appropriate for massage therapy enables cost-effective healthcare access. If such treatments cost is low, it would provide more individuals with an opportunity to enjoy frequent massages which are crucial in relieving anxiety and pain. Because it is cheap, individuals may incorporate such treatments in their healthcare lifestyles without having to be concerned about how much they spend on themselves. At Malayali Kerala Spa Ajman, we are providing all types of massage services @ 99 AED. Visit us today.
The Future of Hair Loss Treatment: Harnessing Stem Cells with Dr. David GreeneDr. David Greene Arizona
Hair loss is no longer a condition that must be endured in silence. Thanks to the groundbreaking work of experts like Dr. David Greene, stem cell therapy is emerging as a powerful tool in the fight against hair loss. With continued research and development, this innovative approach holds the promise of transforming the lives of those affected by hair loss, offering a future where a full head of hair can be restored naturally and effectively.
Benefits:
The joined thumbs accentuate
all the manifestations of the fire
element within your body and mind,
and accelerate their effects, improving
eyesight and digestion, among other
things.
At the same time, the pressure applied to the backs of the fingers serves to decrease the effects of the air and space elements.
Maximize efficiency and accuracy in medical billing with our comprehensive solutions tailored to your practice's needs. Our expert team ensures timely reimbursements and minimized denials, so you can focus on providing quality patient care. visit: www.velanhcs..com
Innovations in Hair Loss Treatment: The Role of R3 Stem CellR3 Stem Cell
R3 Stem Cell is revolutionizing hair loss treatment with cutting-edge regenerative medicine. By harnessing the power of stem cells, R3 Stem Cell offers a novel approach to hair restoration that rejuvenates and regenerates hair follicles. This minimally invasive treatment involves extracting a patient’s own stem cells, processing them, and injecting them into the scalp to stimulate natural hair growth and improve scalp health. Patients experience significant improvements in hair density and thickness, making R3 Stem Cell a leader in effective and natural hair loss solutions.
Database Creation in Clinical Trials: The AI AdvantageClinosolIndia
The use of AI in creating and managing databases for clinical trials offers significant advantages, transforming how data is collected, managed, and analyzed. Here are the key benefits and approaches of leveraging AI in this context
BURNS, CALCULATION OF BURNS, CALCULATION OF FLUID REQUIREMENT AND MANAGEMENT.pdfDolisha Warbi
Nursing assessment of burns, Rule of nine,calculation of fluid by Parkland formula, Brooke formula and Evan's formula, Definition of Burns, causes of burns, classification of burns, pathophysiology of burns, clinical manifestation, Diagnostic evaluation, medical management, surgical management, nursing diagnosis, nursing management, phase of burn care, first aid, complication of burns.
In the healthcare field, precise and comprehensive documentation is essential for delivering high-quality patient care. One of the most critical components of clinical documentation is the SOAP note. At GPAShark.com, we specialize in providing expert SOAP note writing services, tailored to meet the needs of nursing students, healthcare professionals, and medical practitioners. Our goal is to help you master the art of SOAP note writing, ensuring your documentation is thorough, accurate, and effective.
Understanding SOAP Notes
SOAP stands for Subjective, Objective, Assessment, and Plan. This structured method of documentation is used widely in healthcare settings to ensure consistent and clear communication among healthcare providers. Each component of a SOAP note serves a specific purpose:
Subjective (S):
This section captures the patient's narrative, including their chief complaint, history of present illness (HPI), past medical history (PMH), family history (FH), social history (SH), and review of systems (ROS). It reflects the patient's perspective and is crucial for understanding their condition and concerns.
Objective (O):
The objective section includes measurable and observable data collected during the physical examination and diagnostic tests. This might involve vital signs, laboratory results, imaging studies, and physical exam findings. Objectivity is key to providing a factual basis for the assessment.
Assessment (A):
In the assessment section, the healthcare provider synthesizes the subjective and objective data to formulate a diagnosis or differential diagnoses. This analysis helps in understanding the patient's condition and guiding the treatment plan.
Plan (P):
The plan outlines the course of action, including treatment strategies, medications, diagnostic tests, patient education, and follow-up appointments. It provides a roadmap for managing the patient's condition and achieving desired health outcomes.
Why Choose GPAShark.com for SOAP Note Writing?
At GPAShark.com, we recognize the challenges that healthcare students and professionals face in creating detailed and accurate SOAP notes. Our services are designed to support you in various ways:
Expert Writers:
Our team consists of professional writers with advanced nursing degrees (MSN, DNP) and extensive clinical experience. They have a deep understanding of medical terminology, clinical practices, and documentation standards.
Customized Assistance:
We provide personalized support tailored to your specific needs and academic requirements. Whether you need help with a single SOAP note or an entire series, we ensure that each document is crafted with precision and care.
Quality Assurance:
Quality is our top priority. Each SOAP note is thoroughly reviewed and edited to ensure accuracy, clarity, and compliance with healthcare documentation standards. We guarantee high-quality, plagiarism-free work that meets your expectations.
Week 8 Case of Tiana-DIAGNOSIS OF FEEDING AND EATING DISORDERS CASE STUDY.pdfReliable Assignments Help
Struggling with your assignment on the diagnosis of feeding and eating disorders? Look no further! At Reliableassignmentshelp.com, we provide comprehensive support to help you navigate and complete your assignment with ease. Feeding and eating disorders are complex and require a nuanced understanding, and our expert assistance ensures you grasp these complexities effectively.
Why Choose Us?
1. Expert Writers:
Our team is composed of experienced professionals in the fields of psychology, mental health, and medical sciences. They bring a wealth of knowledge and practical insights, ensuring your assignment is handled with the highest level of expertise. Our writers stay updated with the latest research and developments in diagnosing feeding and eating disorders.
2. Comprehensive Support:
We cover a broad spectrum of feeding and eating disorders, including but not limited to:
Anorexia Nervosa
Bulimia Nervosa
Binge-Eating Disorder
Avoidant/Restrictive Food Intake Disorder (ARFID)
Other Specified Feeding or Eating Disorder (OSFED)
Pica and Rumination Disorder
Our assistance extends to understanding the diagnostic criteria outlined in the DSM-5, recognizing the symptoms, and exploring various treatment modalities.
3. Tailored Solutions:
Each assignment we handle is customized to meet your specific requirements and academic standards. We ensure that the content is relevant, accurate, and aligned with your educational goals. Whether you need help with an essay, research paper, case study, or any other assignment type, we provide solutions that are tailored to your needs.
4. Plagiarism-Free Content:
Academic integrity is paramount. We guarantee 100% original work, with proper citations and references. Our content is thoroughly checked for plagiarism to ensure authenticity and originality. You can be confident that your assignment will stand up to scrutiny.
5. Timely Delivery:
We understand the importance of deadlines. Our efficient process ensures that your assignment is completed and delivered on time, without compromising on quality. We offer flexible timelines to accommodate urgent requests as well.
Our Services Include:
1. Detailed Analysis:
We provide an in-depth exploration of various feeding and eating disorders. This includes a comprehensive review of the symptoms, diagnostic criteria, risk factors, and treatment options for each disorder. Our detailed analysis helps you understand the nuances and complexities involved in diagnosing these disorders.
2. Case Studies:
We incorporate real-life examples and case studies to illustrate the variations and intricacies in diagnosing feeding and eating disorders. These case studies enhance your understanding by providing practical, real-world applications of theoretical knowledge.
3. Research Assistance:
Our experts assist you in finding and analyzing relevant academic sources. We help you identify credible research articles, books, and journals that support your assignment.
TEST BANK For Carolyn Jarvis, Physical Examination and Health Assessment 4th ...rightmanforbloodline
TEST BANK For Carolyn Jarvis, Physical Examination and Health Assessment 4th Canadian Edition 2024 Verified Chapters 1 - 31.pdf
TEST BANK For Carolyn Jarvis, Physical Examination and Health Assessment 4th Canadian Edition 2024 Verified Chapters 1 - 31.pdf
TEST BANK For Carolyn Jarvis, Physical Examination and Health Assessment 4th Canadian Edition 2024 Verified Chapters 1 - 31.pdf
World Health Organization Guidelines on Nutrition .pptxMopideviSravani
WHO is the directing and coordinating authority for health. It is responsible for providing
leadership on global health matters, shaping the health research agenda, setting norms and
standards, articulating evidence-based policy options, providing technical support to countries
and monitoring and assessing health trends.
WHO guidelines on Nutrition:
1. Guideline: iron and folic acid supplementation in menstruating women
2. Guideline: iron supplementation in preschool and school-age children
3. Guideline: Neonatal vitamin A supplementation
4. Guideline: Vitamin A supplementation during pregnancy for reducing the risk of mother-tochild transmission of HIV
5. Guideline: Vitamin A supplementation for infants 1-5 months of age
6. Guideline: Vitamin A supplementation in postpartum women
Dawn of new Era: Digital Human, Agentic AI, and Auto sapiensJAI NAHAR, MD MBA
This interactive talk focuses on Intelligent Digital
agents, Digital human, and Embodied agents, which
are important emerging applications of Generative AI
in 2024 and beyond.
Dawn of new Era: Digital Human, Agentic AI, and Auto sapiens
Summary of Revisions: Standards of Care in Diabetes—2024
1. Connected for Life. This slide deck contains content created, reviewed,
and approved by the American Diabetes
Association® (ADA). You are free to use the slides in
presentations without further permission as long as
the slide content is not altered in any way and
appropriate attribution is made to the ADA (the ADA's
name and logo on the slides constitutes appropriate
attribution). Permission is required from the ADA for
any commercial use or for reproduction in any print
materials (contact permissions@diabetes.org).
2. 2
Published annually in Clinical Diabetes
Contains evidence-based recommendations most pertinent to primary care
Recommendations are substantively the same as in the complete Standards of Care
Access:
Abridged Standards of Care — diabetesjournals.org/clinical
Complete Standards of Care and all supporting references — professional.diabetes.org/standards
Abridged for Primary Care Professionals
STANDARDS OF CARE IN DIABETES 2024
4. 4
A multifaceted approach encompassing patient-level, system-level, and policy-level interventions is crucial for enhancing population health
in the context of diabetes. This approach may include the following key elements.
Improving Care and Promoting Health in Populations
STANDARDS OF CARE: SECTION 1
7. 7
Classification
STANDARDS OF CARE: SECTION 2
Classification of diabetes type is not always straightforward at presentation, and misdiagnosis is common.
8. 8
Screening Criteria for Prediabetes and Type 2
Diabetes
STANDARDS OF CARE: SECTION 2
Informal assessment of risk
factors
Validated risk calculator
9. 9
STANDARDS OF CARE: SECTION 2
Informal Risk Factor Assessment for Prediabetes
and Type 2 Diabetes
29. 29
STANDARDS OF CARE: SECTION 5
Building positive health behaviors and maintaining psychological well-being are foundational for achieving diabetes
management goals and maximizing quality of life.
86. 86
STANDARDS OF CARE: SECTION 12
Neuropathy
Treatment
Various drugs may reduce pain from DPN, and both drug and non-drug strategies may
ease symptoms of DPN and autonomic neuropathy.
The safest and most evidence-based pharmacologic options for DPN include
gabapentinoids, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants,
and sodium channel blockers.
Refer to a neurologist or pain specialist when pain control is not achieved within the
scope of practice of the treating clinician.
• There is insufficient evidence to support the use of continuous glucose monitoring for screening or diagnosing prediabetes or diabetes.
• In the absence of unequivocal hyperglycemia (e.g., hyperglycemic crisis), diagnosis of type 2 diabetes requires confirmatory testing, which can be a different test on the same day or the same test on a different day.
• Marked discordance between A1C and repeated blood glucose measurements should raise the possibility of a problem or interference with either test.
Does statin therapy increase the risk of developing type 2 diabetes?
• Statin therapy may slightly elevate type 2 diabetes risk in high-risk individuals.
• In primary and secondary prevention of cardiovascular disease, statin benefits outweigh diabetes risk.
• Discontinuing statins based on concerns about increased diabetes risk is not advised.
Does pioglitazone have a role in secondary cardiovascular prevention in people at risk for type 2 diabetes?
Pioglitazone could reduce stroke and myocardial infarction risks in people with a history of stroke and evidence
of insulin resistance or prediabetes. However, the benefit must be weighed against potential weight gain,
edema, and increased fracture risk. Lower doses may lessen these adverse effects.
Diabetes treatment goals aim to prevent or delay complications and optimize quality of life. These goals should be developed collaboratively with people with diabetes to honor their preferences and values. Comprehensive diabetes care should be provided by an interprofessional team which may include but is not limited to diabetes care and education specialists, primary care and subspecialty clinicians, nurses, registered dietitian nutritionists, exercise specialists, pharmacists, dentists, podiatrists, behavioral health professionals, and community partners such as community health workers and community paramedics. Ongoing treatment necessitates regular follow-up and the active engagement of people with diabetes and their care partners. Comprehensive medical evaluations (described in the table below) and the provision of all recommended vaccinations (cdc.gov/vaccines) are essential components of ongoing diabetes care.
ABI, ankle-brachial pressure index; ARBs, angiotensin receptor blockers; CGM, continuous glucose monitors; MDI, multiple daily injections; NAFLD, nonalcoholic fatty liver disease; OSA, obstructive sleep apnea; PAD, peripheral arterial disease.
*At 65 years of age or older.
+May be needed more frequently in people with diabetes with known chronic kidney disease or with changes in medications that affect kidney function and serum potassium
#May also need to be checked after initiation or dose changes of medications that affect these laboratory values (i.e., diabetes medications, blood pressure medications, cholesterol medications, or thyroid medications).
^In people without dyslipidemia and not on cholesterol-lowering therapy, testing may be less frequent.
**Should be performed at every visit in people with diabetes with sensory loss, previous foot ulcers, or amputations.
ABI, ankle-brachial pressure index; ARBs, angiotensin receptor blockers; CGM, continuous glucose monitors; MDI, multiple daily injections; NAFLD, nonalcoholic fatty liver disease; OSA, obstructive sleep apnea; PAD, peripheral arterial disease.
*At 65 years of age or older.
+May be needed more frequently in people with diabetes with known chronic kidney disease or with changes in medications that affect kidney function and serum potassium
#May also need to be checked after initiation or dose changes of medications that affect these laboratory values (i.e., diabetes medications, blood pressure medications, cholesterol medications, or thyroid medications).
^In people without dyslipidemia and not on cholesterol-lowering therapy, testing may be less frequent.
**Should be performed at every visit in people with diabetes with sensory loss, previous foot ulcers, or amputations.
ABI, ankle-brachial pressure index; ARBs, angiotensin receptor blockers; CGM, continuous glucose monitors; MDI, multiple daily injections; NAFLD, nonalcoholic fatty liver disease; OSA, obstructive sleep apnea; PAD, peripheral arterial disease.
*At 65 years of age or older.
+May be needed more frequently in people with diabetes with known chronic kidney disease or with changes in medications that affect kidney function and serum potassium
#May also need to be checked after initiation or dose changes of medications that affect these laboratory values (i.e., diabetes medications, blood pressure medications, cholesterol medications, or thyroid medications).
^In people without dyslipidemia and not on cholesterol-lowering therapy, testing may be less frequent.
**Should be performed at every visit in people with diabetes with sensory loss, previous foot ulcers, or amputations.
ABI, ankle-brachial pressure index; ARBs, angiotensin receptor blockers; CGM, continuous glucose monitors; MDI, multiple daily injections; NAFLD, nonalcoholic fatty liver disease; OSA, obstructive sleep apnea; PAD, peripheral arterial disease.
*At 65 years of age or older.
+May be needed more frequently in people with diabetes with known chronic kidney disease or with changes in medications that affect kidney function and serum potassium
#May also need to be checked after initiation or dose changes of medications that affect these laboratory values (i.e., diabetes medications, blood pressure medications, cholesterol medications, or thyroid medications).
^In people without dyslipidemia and not on cholesterol-lowering therapy, testing may be less frequent.
**Should be performed at every visit in people with diabetes with sensory loss, previous foot ulcers, or amputations.
Hypoglycemia is categorized into three levels based on blood glucose concentrations and symptom severity. Level 1 is glucose <70 mg/dL (<3.9 mmol/L) but ≥54 mg/dL (≥3.0 mmol/L). Level 2 is glucose <54 mg/dL (<3.0 mmol/L). Level 3 is a severe event characterized by altered mental and/or physical status requiring assistance for treatment of hypoglycemia, irrespective of glucose level.
Hypoglycemia is categorized into three levels based on blood glucose concentrations and symptom severity. Level 1 is glucose <70 mg/dL (<3.9 mmol/L) but ≥54 mg/dL (≥3.0 mmol/L). Level 2 is glucose <54 mg/dL (<3.0 mmol/L). Level 3 is a severe event characterized by altered mental and/or physical status requiring assistance for treatment of hypoglycemia, irrespective of glucose level.
Learn More
Section 7 of the complete ADA Standards of Care in Diabetes—2024 includes a wealth of additional information on blood glucose meters, evidence supporting the use of CGM, various insulin delivery systems, and digital health apps and online programs.
* In people with HF, CKD, established CVD, or multiple risk factors for CVD, the decision to use a GLP-1 RA or SGLT2i with proven benefit should be independent of background use of metformin;† A strong recommendation is warranted for people with CVD and a weaker recommendation for those with indicators of high CV risk. Moreover, a higher absolute risk reduction and thus lower numbers needed to treat are seen at higher levels of baseline risk and should be factored into the shared decision-making process. See text for details; ^ Low-dose TZD may be better tolerated and similarly effective; § For SGLT2i, CV/renal outcomes trials demonstrate their efficacy in reducing the risk of composite MACE, CV death, all-cause mortality, MI, HHF, and renal outcomes in individuals with T2D with established/high risk of CVD; # For GLP-1 RA, CVOTs demonstrate their efficacy in reducing composite MACE, CV death, all-cause mortality, MI, stroke, and renal endpoints in individuals with T2D with established/high risk of CVD.
ACEi, angiotensin-converting enzyme inhibitor; ACR, albumin-to-creatinine ratio; ARB, angiotensin receptor blocker; ASCVD, atherosclerotic cardiovascular disease; CGM, continuous glucose monitoring; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; CVOT, cardiovascular outcomes trial; DPP-4i, dipeptidyl peptidase 4 inhibitor; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide 1 receptor agonist; dual GIP/GLP-1 RA, dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HHF, hospitalization for heart failure; MACE, major adverse cardiovascular events; MI, myocardial infarction; SDOH, social determinants of health; SGLT2i, sodium-glucose cotransporter 2 inhibitor; T2D, type 2 diabetes; TZD, thiazolidinedione. Adapted from Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41:2669–2701.
Atherosclerotic cardiovascular disease (ASCVD), encompassing coronary heart disease, cerebrovascular disease, and peripheral artery disease (PAD) presumed to be of atherosclerotic origin, is the primary cause of morbidity and mortality in individuals with diabetes, leading to significant health care costs. Managing multiple risk factors simultaneously can prevent or slow the progression of ASCVD. Heart failure is another major cause of morbidity and mortality from cardiovascular disease.
Legend: *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is suggested to treat hypertension for people with coronary artery disease (CAD) or urine albumin-to-creatinine ratio (UACR) 30–299 mg/g creatinine and strongly recommended for individuals with UACR ≥300 mg/g creatinine. †Dihydropyridine calcium channel blocker (CCB). ‡Thiazide-like diuretic; long-acting agents shown to reduce cardiovascular events, such as chlorthalidone and indapamide, are preferred. BP, blood pressure. Adapted from de Boer IH, Bangalore S, Benetos A, et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care 2017;40:1273–1284
eGFR is presented in units of mL/min/1.73 m2. *ACEi or ARB (at maximal tolerated doses) should be first-line therapy for hypertension when albuminuria is present. Otherwise, dihydropyridine CCB or diuretic can also be considered; all three classes are often needed to attain BP targets. †Finerenone is currently the only nonsteroidal MRA with proven clinical kidney and cardiovascular benefits. ACEi, ACE inhibitor; ACR, albumin-to creatinine ratio; ARB, angiotensin receptor blocker; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; CCB, calcium channel blocker; CVD, cardiovascular disease; GLP-1 RA, glucagon-like peptide 1 receptor agonist; HTN, hypertension; MRA, mineralocorticoid receptor antagonist; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor; RAS, renin- angiotensin system; SGLT2i, sodium–glucose cotransporter 2 inhibitor; T1D, type 1 diabetes; T2D, type 2 diabetes. Adapted from de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022;45:3075–3090.
Algorithm to simplify insulin plans for older adults with type 2 diabetes. eGFR, estimated glomerular filtration rate. *Basal insulins: glargine U-100 and U-300, detemir, degludec, and human NPH. †Prandial insulins: short-acting (regular human insulin) or rapid-acting (lispro, aspart, and glulisine). ‡Premixed insulins: 70/30, 75/25, and 50/50 products. §Examples of noninsulin agents include metformin, sodium–glucose cotransporter 2 inhibitors, dipeptidyl peptidase 4 inhibitors, and glucagon-like peptide 1 receptor agonists. ||See previous page for more information. Adapted with permission from Munshi MN, Slyne C, Segal AR, Saul N, Lyons C, Weinger K. Simplification of insulin regimen in older adults and risk of hypoglycemia. JAMA Intern Med 2016;176:1023–1025.
Management of new-onset diabetes in you with overweight or obesity with clinical suspicion of type 2 diabetes. A1C 8.5% = 69 mmol/mol. Adapted from Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American Diabetes Association. Diabetes Care 2018;41:2648–2668. BGM, blood glucose monitoring; DKA, diabetic ketoacidosis: HHNK, hyperosmolar hyperglycemic nonketotic syndrome; IV, intravenous; MDI, multiple daily injection.
The preconception care of people with diabetes is detailed in Table 15.1 in the complete ADA Standards of Care in Diabetes—2024.